Comparative analysis of point-of-care lateral flow immunoassays for the detection of IgM and 1 IgG anti-SARS-CoV-2 antibodies in healthcare workers 2 3 4 Danielle Dias Conte¹, Joseane Mayara Almeida Carvalho¹, Luciano Kleber de Souza Luna*¹, Klinger Soares Faíco-Filho¹, Ana Helena Perosa², Nancy Bellei¹. 5 6 7 ¹Department of Medicine, Discipline of infectious diseases, Universidade Federal de São Paulo 8 ²Universidade Federal de São Paulo, Hospital São Paulo 9 10 *Corresponding author: Luciano Kleber de Souza Luna Universidade Federal de São Paulo, Laboratório de Virologia Clínica. Rua Pedro de Toledo, Rua 11 12 Pedro de Toledo, 781 - Vila Clementino. 04039-032, São Paulo, SP, Brazil. Phone: + 55 11 5576-4848, branch 2222. E-mail: lksluna@gmail.com 13 14 15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

Abstract Since the Coronavirus Disease 2019 (COVID-19) pandemic, Brazil has the third-highest number of confirmed cases and the second-highest number of recovered patients. SARS-CoV-2 detection by real-time RT-PCR is the gold standard in certified infrastructured laboratories. However, for largescale testing, diagnostics should be fast, cost-effective, widely available, and deployed for the community, such as serological tests based on lateral flow immunoassay (LFIA) for IgM/IgG detection. We evaluated three different commercial point-of-care (POC) LFIAs for anti-SARS-CoV-2 IgM and IgG detection in capillary whole blood of 100 healthcare workers (HCW) previously tested by RT-PCR: 1) COVID-19 IgG/IgM BIO (Bioclin, Brazil), 2) Diagnostic kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Livzon, China); and 3) SARS-CoV-2 Antibody Test (Wondfo, China). A total of 84 positives and 16 negatives HCW were tested. The data was also analyzed by the number of days after symptoms (DAS) in three groups: <30 (n=26), 30-59 (n=42), and >59 (n=16). Overall detection was 85.71%, 47.62%, and 44.05% for Bioclin, Livzon, and Wondfo, respectively, with a specificity of 100%, and 98.75% for Livzon on storage serum samples. Bioclin was more sensitive (p<0.01), regardless of the DAS. Thus, the Bioclin can be used as a POC test to monitor SARS-CoV-2 seroconversion in HCW. **Keywords**: SARS-CoV-2 detection, point-of-care, lateral flow immunoassay, healthcare workers.

1. Introduction

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

After almost seven months since the Coronavirus Disease 2019 (COVID-19) pandemic, caused by de the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Brazil reached, until late August 2020, the second place in the number of confirmed cases. Currently (on September 15, 2020), in the third position, accounts for 4,345,610 confirmed cases, with 132,006 deaths, and is the second country with the highest number of recovered patients (3,770,138) (Dong, Du, and Gardner, 2020). The molecular detection of SARS-CoV-2 by real-time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) is the gold standard test but requires a certified laboratory infrastructure with high-cost equipment and trained personnel. This structure is suitable, and of paramount importance. for the diagnostic of hospitalized patients, as well as healthcare workers (HCW), However, for large-scale testing, RT-PCR is not the best option. Therefore, COVID-19 diagnostic tests should be fast, cost-effective, widely available, and deployed for the community. In general, those requisites are achieved by serological tests based on lateral flow immunoassay (LFIA). Many LFIAs have been described for the detection of IgM and IgG immunoglobulins against SARS-CoV-2 (Vashist, 2020). Immunoglobulin response against viral infection begins with an early and transient IgM production, followed by a longer and lasting IgG response. In patients with COVID-19, the production of IgM and IgG could be simultaneous and detected after two days of symptoms onset, and could reach in some patients a plateau level after six days (Long et al., 2020; Zhao et al., 2020). Moreover, the immunoglobulin levels are correlated positively with the severity of COVID-19 although the antibody response could be delayed in critical patients compared to non-critical cases (Qu et al., 2020). In the present study, we evaluated the sensitivity of three different commercial Point-of-care (POC) LFIAs for anti-SARS-CoV-2 antibody detection, in HCW with confirmed tests (positive or negative) for COVID-19 by RT-PCR assay.

2. Material and methods

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

Three commercial POC LFIAs for detection of anti-SARS-CoV-2 IgG and IgM were tested: 1) COVID-19 IgG/IgM BIO (Bioclin, Brazil), 2) Diagnostic kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Livzon, China); and 3) SARS-CoV-2 Antibody Test (Wondfo, China). Bioclin and Livzon LFIAs independently detect IgG and IgM, whereas Wondfo detects IgG and IgM combined. A total of 100 HCW from University Hospital São Paulo, previously tested for SARS-CoV-2 infection by real-time RT-PCR, were enrolled in the study. From them, 84 were confirmed positive, and 16, negative. Furthermore, 80 storage serum samples, collected during 2018 and 2019, were also tested with Livzon LFIA, the only test available for this additional analysis. The indicated volume of capillary whole blood for each test, collected preferably from the skin of annular fingertip with a lancing device, was added immediately into the cassette sample wells, following the addition of sample diluent according to the manufacturer instructions. All LFIAs were tested simultaneously in the moment of blood draw of each investigated HCW. Similarly, the recommended serum volume for testing the 80 storage serum samples with Livzon LFIA was also applied accordingly. Results were read within 1-15 minutes. Sensitivity was calculated as the proportion of positive results of LFIAs in relation to the positive RT-PCR confirmed cases, and specificity was calculated as the proportion of LFIAs negative results in relation to the negative RT-PCRs. The 95% confidence intervals (CI) of sensitivity and specificity proportions were calculated by the modified Wald method. The results were also analyzed according to the number of days after symptoms (DAS), distributed in three distinct groups: <30 (n=26), 30-59 (n=42), and >59 (n=16). The proportion of results accounted for IgM and IgG, alone or combined, regarding DAS, and pairwise comparison within LIFAs was analyzed by Cochran's Q and McNemar tests, for a p-value <0.05. The analysis was made using software R version 4.0.2 (Team, 2020). The study was approved by the São Paulo hospital Research Ethics Committee (CEP n. 34371020.5.0000.5505).

3. Results

- The age of investigated HCWs varied from 20 to 67 yeas (mean = 37.45, median = 36). Overall
- detection of IgM and IgG, individually or combined, are described in table 1.

Table 1: Comparison of LFIAs results with 84 positive RT-PCR for SARS-CoV-2.

LFIA -	number / Sensitivity in % (95% CI)					
	IgG/IgM	IgM	IgG			
Bioclin	72 / 85.71 (76.52-91.79)	46 / 54.76 (44.14-64.97)	72 / 85.71 (76.52-91.79)			
Livzon	40 / 47.62 (37.28-58.17)	25 / 29.76 (21.01-40.29)	54 / 35.71 (26.28-46.40)			
Wondfo	37 / 44.05 (33.92-54.70)	N.A.	N.A.			

- N.A., not available.
- In general, Bioclin LFIA showed the highest sensitivity (85.71%), followed by Livzon (47.62%)
- and Wondfo (44.05%).
- In comparison to the 16 negative RT-PCR individuals, the sensitivity of all LFIAs was 100%
- (77.31% to 100%, 95% CI). However, one storage serum sample from 2018 was IgG reagent by
- Livizon LFIA and therefore the sensitivity of this additional test was 98.75% (92.59% to 99.99%,
- 95% CI).

The results according to the groups of DAS (<30, 30-59, and >59), are depicted in table 2.

perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2: Comparison of LFIAs results in time groups according to the days after symptoms (DAS).

Antibody	DAS	HCW	number (%)			n valor
Allubouy			Bioclin	Wondfo	Livzon	p-valor
IgM/IgG ¹	<30	26	22 (88.00)	14 (56.00)	13 (52.00)	0.0022*
	30-59	42	38 (88.37)	21 (48.84)	17 (39.53)	< 0.001*
	>59	16	12 (75.00)	5 (31.25)	7 (43.75)	0.0131*
IgM ²	<30	26	19 (76.00)	NA	11 (44.00)	0.0047*
	30-59	42	21 (48.84)	NA	11 (25.58)	0.03892*
	>59	16	6 (37.50)	NA	3 (18.75)	0.0833
IgG ²	<30	26	22 (88.00)	NA	10 (44.00)	0.0005*
	30-59	42	38 (88.37)	NA	15 (34.88)	< 0.001*
	>59	16	12 (75.00)	NA	5 (31.25)	0.0081

DAS, days after symptoms. HCW, healthcare workers.

The Bioclin LFIA was significantly more sensitive, in comparison to Livzon and Wondfo, regardless of the DAS or detection of IgM and IgG combined (Cochran's Q test, p<0.05). The posthoc analysis of pairwise comparisons with McNemar tests also have shown that Bioclin was more sensitive than Livzon and Wondfo for IgM and IgG individually, and no differences were observed between Livzon and Wondfo regardless of the DAS or immunoglobulin class (table 2). The proportion of positives within each LFIA in relation to the DAS have shown any significant difference for overall IgM and IgG detection (Bioclin, p=0.316; Livzon, p=0.744; Wondfo, p=0,33), IgG alone (Bioclin, p=0.316; Livzon, p=0.894), or IgM (Bioclin, p=0.054; Livzon, p=0.208), although Bioclin is likely to be more sensitive for IgM in the group of <30 (p=0.054).

^{*} significant for p<0.05

^{113 &}lt;sup>1</sup>Cochran's Q test, p<0.05

²McNemar test, p<0.05

4. Discussion

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

In the present study, we analyzed three different commercial LFIAs for the detection of anti-SARS-CoV-2 IgG and IgM in HCW. For the POC test format, capillary whole blood is more suitable than serum or plasma and does not require a laboratory infrastructure for venous blood draw. The use of POC based tests for rapid antibody detection can be helpful in identifying patients at different stages of infection, due to the early production of IgM followed by IgG response, even though in patients with COVID-19 the IgM and IgG response could be simultaneous. Our results demonstrated that overall sensitivity achieved by Bioclin LFIA (85.71%) with whole blood samples is compared to those obtained with serum or plasma, in contrast to Livzon and Wondfo LFIAs which showed sensitivities below 50% (Costa et al., 2020; Santos et al., 2020; Silveira et al., 2020; Tuaillon et al., 2020). Similar to the results here described, Santos et al. (2020) have shown, for capillary whole blood, a sensitivity of 55% for the Wondfo LFIA test in HCWs. On the other hand, the detection sensitivity in serum samples was much higher (96%). In a larger study with hospitalized patients, Costa et al. (2020) evaluated the Wondfo LFIA, in serum samples or plasma, and obtained a sensitivity of 85.8%. In another evaluation of the Wondfo LFIA, Wu et al. (2020) have shown a sensibility of 75.8% in serum samples. In the same manner, Livzon LFIA, when tested in serum samples of hospitalized patients, presented a sensibility of 80% for IgM and 86.7 for IgG, with a specificity of 95% and 100% respectively. An advantage of the present study is due to the fact that all LFIAs were carried out simultaneously at the time of blood draw from each HCW. On the other hand, a limitation of the study was the impossibility of follow up on each HCW to observe possible variations in the detection of IgM and IgG over time, or to expand the study to include hospitalized patients or low-income individuals from the general community.

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

5. Conclusion Bioclin LFIA demonstrated high sensitivity and specificity for IgG detection (85.71%), and a reasonable detection of IgM (54.76%), with the use of capillary whole blood in HCW. On the other hand, Livzon and Wondfo LFIAs presented overall sensitivity below 50%. Thus, the Bioclin LFIA is a suitable POC test to monitor SARS-CoV-2 seroconversion in HCW. Acknowledgments J.M.A.C. and L.K.S.L. are fellows of the Coordenação de Aperfeiçoamento de Pessoal deNível Superior (CAPES), Brazil. D.D.C. is a fellow of the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil. We are grateful to Anderson Scorsato for the statistical support. **Declarations of interest:** none **CRediT** authorship contribution statement Danielle D. Conte: Validation, Investigation, Data Curation, Writing - Original Draft. Joseane M. A. Carvalho: Investigation, Data Curation. Luciano K. de Souza Luna: Validation, Investigation, Formal analysis, Writing - Review & Editing, Visualization. Klinger S. Faíco-Filho: Investigation. Ana H. S. Perosa: Investigation. Nancy Bellei: Conceptualization, Methodology, Resources, Supervision, Writing - Review & Editing, Project administration, Funding acquisition.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

References

182

198

199

200

201

202

203

204

205206

207

208

209

210

213

214

215

- Costa, S.F., Buss, L., Espinoza, E.P.S., Vieira, J.M., Jr., de Oliveira da Silva, L.C., de Souza, R.M., Neto, L.P., Porto,
 A.P.M., Lazari, C., Dos Santos, V.A., da Silva Duarte, A., Nastri, A.C., da Costa Leite, G.F., Manuli, E.,
 de Oliveira, M.S., Zampelli, D.B., Pastore, L.J., Segurado, A.C., Levin, A.S. and Sabino, E., 2020.
 Performance of a qualitative rapid chromatographic immunoassay to diagnose COVID-19 in patients
 in a middle-income country. J Clin Virol 131, 104592.
- Dong, E., Du, H. and Gardner, L., 2020. An interactive web-based dashboard to track COVID-19 in real time.

 Lancet Infect Dis 20, 533-534.
- Long, Q.X., Liu, B.Z., Deng, H.J., Wu, G.C., Deng, K., Chen, Y.K., Liao, P., Qiu, J.F., Lin, Y., Cai, X.F., Wang, D.Q.,
 Hu, Y., Ren, J.H., Tang, N., Xu, Y.Y., Yu, L.H., Mo, Z., Gong, F., Zhang, X.L., Tian, W.G., Hu, L., Zhang,
 X.X., Xiang, J.L., Du, H.X., Liu, H.W., Lang, C.H., Luo, X.H., Wu, S.B., Cui, X.P., Zhou, Z., Zhu, M.M.,
 Wang, J., Xue, C.J., Li, X.F., Wang, L., Li, Z.J., Wang, K., Niu, C.C., Yang, Q.J., Tang, X.J., Zhang, Y., Liu,
 X.M., Li, J.J., Zhang, D.C., Zhang, F., Liu, P., Yuan, J., Li, Q., Hu, J.L., Chen, J. and Huang, A.L., 2020.
 Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 26, 845-848.
- 196 Qu, J., Wu, C., Li, X., Zhang, G., Jiang, Z., Li, X., Zhu, Q. and Liu, L., 2020. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis.
 - Santos, V.A.D., Rafael, M.M., Sabino, E.C. and Duarte, A., 2020. Sensitivity of the Wondfo One Step COVID-19 test using serum samples. Clinics (Sao Paulo) 75, e2013.
 - Silveira, M.F., Barros, A.J.D., Horta, B.L., Pellanda, L.C., Victora, G.D., Dellagostin, O.A., Struchiner, C.J., Burattini, M.N., Valim, A.R.M., Berlezi, E.M., Mesa, J.M., Ikeda, M.L.R., Mesenburg, M.A., Mantesso, M., Dall'Agnol, M.M., Bittencourt, R.A., Hartwig, F.P., Menezes, A.M.B., Barros, F.C., Hallal, P.C. and Victora, C.G., 2020. Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil. Nat Med 26, 1196-1199.
 - Team, R.C. 2020. R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria.
 - Tuaillon, E., Bollore, K., Pisoni, A., Debiesse, S., Renault, C., Marie, S., Groc, S., Niels, C., Pansu, N., Dupuy, A.M., Morquin, D., Foulongne, V., Bourdin, A., Le Moing, V. and Van de Perre, P., 2020. Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients. J Infect 81, e39-e45.
- Vashist, S.K., 2020. In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends.
 Diagnostics (Basel) 10.
 - Wu, J.L., Tseng, W.P., Lin, C.H., Lee, T.F., Chung, M.Y., Huang, C.H., Chen, S.Y., Hsueh, P.R. and Chen, S.C., 2020. Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2. J Infect.
- Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., Qian, S., Hong, C., Wang,
 F., Liu, Y., Wang, Z., He, Q., Li, Z., He, B., Zhang, T., Fu, Y., Ge, S., Liu, L., Zhang, J., Xia, N. and Zhang,
 Z., 2020. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect
 Dis.